The economic burden of prostate cancer in Canada: Forecasts from the Montreal Prostate Cancer Model

CMAJ. Canadian Medical Association Journal

Volumn 162, Issue 7, 2000, Pages 987-992

  Grover, Steven A ^a   Coupai, Louis ^a   Zowall, Hanna ^b   Rajan, Raghu ^c   Trachtenberg, John ^d   Elhilali, Mostafa ^a   Chetner, Michael ^b   Goldenberg, Larry ^c  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANADA; CANCER RISK; ECONOMIC ASPECT; FORECASTING; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MODEL; ORCHIECTOMY; PROSTATE CANCER; PROSTATECTOMY;

EID: 0034603847     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Steering Committee for Canadian Cancer Statistics. Cancer incidence and mortality, 1997. Health Rep 1997;8(4):41-51.
2. Grover SA, Zowall H, Coupai L, Krahn MD. Prostate cancer: 12. The economic burden. CMAJ 1999;160(5):685-90.
3. Grover SA, Coupai L, Zowall II, Rajan R, Trachtenberg J, Elhilali M, et al. The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. at472000;162(7):977-83.
4. Cancer in Canada 1991. Ottawa: Health Statistics Division, Statistics Canada; -1995. Cat no 82-218.
5. Mettlin CJ, Alurphy GP, McGinnis LS, Menck HR: The National Cancer Data Base report on prostate cancer. American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1995;76:1104-12.
6. Mettlin CJ, Murphy GP, Ho R, Menck HR. The National Cancer Data Base report on longitudinal observations on prostate cancer. Cancer 1996;77:2162-6.
7. Mellinger GT, Gleason D, Bailar J III. The histology and prognosis of prostatic cancer. 7 Ural 1967;97:331-7.
8. Jones GW, Mettlin C, Murphy GP, Guinan P, Herr HW, Hussey DH, et al. Patterns of care for carcinoma of the prostate gland: results of a national survey of 1984 and 1990. J Am Coll Surg 1995; 180:545-54.
9. Lu-Yao GL, McLerran D, Wasson J, WennbergJE. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA 1993;269:2633-6.
10. Lubke WL, Optenberg SA, Thompson IM. Analysis of the first-year cost of a prostate cancer screening and treatment program in the United States. J Natl Cancer last 1994;86:1790-2.
11. Wasson JH, Cushman CC, Bruskewitz RC, Littenberg B, Mulley AG Jr, WennbergJE. A structured literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team [published erratum appears in Arch FamMeJl99);2(lO):l030]. Arch FamMed 1993;2-AS7-93.
12. Fowler FJ Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg E. Patient-reported complications and follow-up treaunent after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology 1993;42:622-9.
13. Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE, et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. IntJ Radial OmoIBioIPhys 1991;21:935-9.
14. Mettlin CJ, Murphy G. The National Cancer Data Base report on prostate cancer. Cancer 1994;74:1640-8.
15. Lu-Yao GL, Potosky AL, Albertsen PC, U'asson JH, Barry MJ, Wennberg JE. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Nail Cancer Ina 1996;88:166-73.
16. Fowler FJ Jr, Barry MJ, Lu-Yao G, Wasson JH, Bin L. Outcomes of external-beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas. J Clin Oncol 1996;14:2258-65.
17. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteenyear survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997;277:467-71.
18. Gerber GS, Thisted RA, Scardino PT, Frohmuller I IG, Schroeder FI I, Paulson DF, et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 1996;276:615-9.
19. Ferez CA, Pilepich MV, Garcia D, Simpson JR, Zivnuska F, Hedcrman MA. Definitive radiation therapy in carcinoma of the prostate localized to the pelvis: experience at the Mallincfcrodt Institute of Radiology. KCIMonogr 1988;7:85-94.
20. Chodak GW, Thisted RA, Gerber GS, Johansson JE, AdolfssonJ, Jones GW, et al. Results of conservative management of clinically localized prostate cancer. NEnglJMed 1994;330:242-8.
21. Lee RJ, Sause WT. Surgically staged patients with prostatic carcinoma treated with definitive radiotherapy: fifteen-year results. Urology 1994;43:640-4.
22. Life tables, Canada and Provinces 1990-1992. Ottawa: Statistics Canada; 1995. Cat no 84-537.
23. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine [review]. JAMA 1996;276:1253-8.
24. Mettlin C, Jones GW, Murphy GP. Trends in prostate cancer care in the United States, 1974-1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA Cancer J Clin 1993;43:83-91.
25. 'Manuel des médecins omnipraticiens. Quebec City: Régie de Passurance-maladie du Québec; 1996.
26. Manuel des médecins spécialistes. Québec City: Régie de l'assurance-maladie du Québec; 1996.
27. Schedule of benefits: physician services, 1992. Toronto: Ontario Ministry of Health; 1992.
28. National health expenditures in Canada 1915-1994. Ottawa: Health Canada; 1996. Cat no H21-99/1994.
29. Hospital statistics: preliminary annual report, 1994-95. Ottawa: Health Statistics Division, Statistics Canada; 1996. Cat no 83-241-XMB.
30. Resource Intensity Weights. Summary of methodology, 1996/97. Ottawa: Canadian Institute for Health Information; 1996.
31. Screcningfor cancer of prostate: an evaluation of benefits, unwanted health effects and costs. Montreal: Conseil d'évaluation des technologies de la santé du Québec; 1995.
32. Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B, et al. Use of palliative end points to evaluate the effects of mitoxantrone and lowdose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 1994;12:689-94.
33. Wodinsky HB, Jenkin RDT. The cost of radiation treatment at an Ontario regional cancer center. CMAJ 1987;137(10):906-9.
34. Aus G, Hugosson J, Norlen L. Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent. J Urol 1995; 154(2 pt l):466-9.
35. Denis LJ, Carnelro de Moura JL, Bono A, Sylvester R, Whelan P, Newling D, et al. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 1993;42:119-29.
36. Otnes B, Harvei S, Fossa SD. The burden of prostate cancer from diagnosis until death. BrJ Urol 1995;76:587-94.
37. Klotz LH, editor. Treatment of disseminated disease. In: Managing prostate cancer. Montreal: Grosvenor House Press; 1992.
38. Krahn MD, MahoneyJE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer. A decision analytic view. JAMA 1994;272:773-80.
39. Compendium of pharmaceuticals and specialties. 31st ed. Ottawa: Canadian Pharmaceutical Association; 1996.
40. To T. Orchidectomy and hormonal therapy of prostate cancer. Can J Urol 1995;2(I):109-15.
41. Canadian compuscript, January-December 1996. Pointe-Claire (QQ: IMS Canada; 1996.
42. Population projections for Canada, Provinces and Territories: 1993-2016. Ottawa: Statistics Canada; 1994. Cat no 91-520.
43. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997;349:906-10.
44. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 199J;274(8):626-31.
45. Canadian cancer statistics 1997. Toronto: National Cancer Institute of Canada; 1997.
46. Barry MJ, Fleming C, Coley CM, Wasson JH, Fahs MC, Oesterling JE. Should Aledicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part I: Framing the debate. Urology 1995;46(1):2-13.
47. Barry MJ, Fleming C, Coley CM, Wasson JH, Fahs MC, Oesterling JE. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part 111: Management strategies and outcomes. Urology 1995;46(3):277-89.
48. Miles BJ, Kattan MW. Computer modeling of prostate cancer treatment. A paradigm for oncologic management? [review] Sitrg Oncol Clin North Am 1995;4(2):361-72.
49. AusG, Pileblad E, HugossonJ. Impact of competing mortality on the cancerrelated mortality in localized prostate cancer, urology 1995;46:672-5.
50. Cow en ME, Chartrand M, Weitzel WF. A Markov model of the natural history of prostate cancer. J Clin Epidaniol 1994;47:3-21.
51. Fleming C, Wasson JH, Albertsen PC, Barry AIJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Tezm.JAMA 1993;269:2650-8.
52. Coley CM, Barry MJ, Fleming C, Mulley AG. Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. American College of Physicians, [review] Ann Intern Med 1997;126:394-406.
53. Coley CM, Barry MJ, Fleming C, Fahs MC, Mulley AG. Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians. Ann Intern Med 1997;126:468-79.
54. Cost and effectiveness of prostate cancer screening in elderly men. Washington: Office of Technology Assessment, Congress of the United States; 1995. Publ no OTA-BP-H-154.
55. Zagars GK, von Eschenbach AC, Johnson DE, Oswald MJ. Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Cancer 1987;60:1489-99.
56. Chamberlain J, Melia J, Moss S, Brown J. Report prepared for the Health Technology Assessment Panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales [review]. BrJ Urol 1997;79(Suppl 3):l-32.
57. National health expenditure trends, 1915-1991. Ottawa: Canadian Institute for Health Information; 1997.
58. Denmeade SR, Isaacs JT. Prostate cancer: Were are we and where are we going? [review] BrJ Urol 1997;79(Suppl l):2-7.
59. Hugosson J, Aus G, Norlen L. Surveillance is not a viable and appropriate treatment option in the management of localized prostate cancer [review]. Urol Clin North Am 1996;23(4):557-73.
60. Hugosson J, Aus G. Natural course of localized prostate cancer. A personal view with a review of published papers [review]. Anticancer Res 1997;17:1441-8.
61. McNaughton Collins M, Ransohoff DF, Barry MJ. Early detection of prostate cancer. Serendipity strikes ûgùn.JAMA I997;278:1516-9.